JP2019516759A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019516759A5 JP2019516759A5 JP2018561557A JP2018561557A JP2019516759A5 JP 2019516759 A5 JP2019516759 A5 JP 2019516759A5 JP 2018561557 A JP2018561557 A JP 2018561557A JP 2018561557 A JP2018561557 A JP 2018561557A JP 2019516759 A5 JP2019516759 A5 JP 2019516759A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- compound
- cycloalkyl
- arbitrary
- independently selected
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 C*C([C@@](CC1)CN1c1cc2cccc(*)c2cn1)=O Chemical compound C*C([C@@](CC1)CN1c1cc2cccc(*)c2cn1)=O 0.000 description 2
- RKWSMOBCWOSVOU-UHFFFAOYSA-N CC(C)[n]1c(cccc2)c2c(-c2n[n](C)c(CC3)c2CN3C(C)=O)c1 Chemical compound CC(C)[n]1c(cccc2)c2c(-c2n[n](C)c(CC3)c2CN3C(C)=O)c1 RKWSMOBCWOSVOU-UHFFFAOYSA-N 0.000 description 1
- GSGFUJNUHRGDLF-UHFFFAOYSA-O CC(N(CC1)CC(C(c(c2c3ccnc2)ccc3F)=[NH2+])=C1NC1CCOCC1)=O Chemical compound CC(N(CC1)CC(C(c(c2c3ccnc2)ccc3F)=[NH2+])=C1NC1CCOCC1)=O GSGFUJNUHRGDLF-UHFFFAOYSA-O 0.000 description 1
- WZEAWVAERAAIEX-UHFFFAOYSA-O CC(N(CC1)CC(C(c(cc2)c(cncc3)c3c2Cl)=[NH2+])=C1NC1CCOCC1)=O Chemical compound CC(N(CC1)CC(C(c(cc2)c(cncc3)c3c2Cl)=[NH2+])=C1NC1CCOCC1)=O WZEAWVAERAAIEX-UHFFFAOYSA-O 0.000 description 1
- WIXFKVSMBGUBTA-IBGZPJMESA-N CC(N(CC1)CC(C(c2c(C)[nH]c3c2ccc(-c2c[n](C)nc2)c3)=N)=C1N[C@@H]1COCC1)=O Chemical compound CC(N(CC1)CC(C(c2c(C)[nH]c3c2ccc(-c2c[n](C)nc2)c3)=N)=C1N[C@@H]1COCC1)=O WIXFKVSMBGUBTA-IBGZPJMESA-N 0.000 description 1
- QSUIOQYCNLHTQS-RWENNGKJSA-N CC(N(CC1)CC(C(c2c(C)[nH]c3c2ccc(/C(/CN)=C/NC)c3)=N)=C1NC1COCC1)=O Chemical compound CC(N(CC1)CC(C(c2c(C)[nH]c3c2ccc(/C(/CN)=C/NC)c3)=N)=C1NC1COCC1)=O QSUIOQYCNLHTQS-RWENNGKJSA-N 0.000 description 1
- JHLUQWDELJFYRE-UHFFFAOYSA-O CC(N(CC1)CC(C(c2c(cnc(N3CCCC3)c3)c3ccc2)=[NH2+])=C1NC1CCOCC1)=O Chemical compound CC(N(CC1)CC(C(c2c(cnc(N3CCCC3)c3)c3ccc2)=[NH2+])=C1NC1CCOCC1)=O JHLUQWDELJFYRE-UHFFFAOYSA-O 0.000 description 1
- AGWQHAZGGMNEOF-UHFFFAOYSA-O CC(N(CC1)CC(C(c2c[nH]c(cc3)c2cc3-c2c[n](C)nc2)=[NH2+])=C1NC)=O Chemical compound CC(N(CC1)CC(C(c2c[nH]c(cc3)c2cc3-c2c[n](C)nc2)=[NH2+])=C1NC)=O AGWQHAZGGMNEOF-UHFFFAOYSA-O 0.000 description 1
- IWHQCMQFHRHPNR-UHFFFAOYSA-O CC(N(CC1)CC(C(c2cc(-c3c[n](C)nc3)ccc2)=[NH2+])=C1NC)=O Chemical compound CC(N(CC1)CC(C(c2cc(-c3c[n](C)nc3)ccc2)=[NH2+])=C1NC)=O IWHQCMQFHRHPNR-UHFFFAOYSA-O 0.000 description 1
- JKNCXBMKAJLWHN-UHFFFAOYSA-O CC(N(CC1)CC(C(c2ccc(C)c3c2cc[nH]3)=[NH2+])=C1NC)=O Chemical compound CC(N(CC1)CC(C(c2ccc(C)c3c2cc[nH]3)=[NH2+])=C1NC)=O JKNCXBMKAJLWHN-UHFFFAOYSA-O 0.000 description 1
- IXQWNXJLNOFSRE-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C)nc2-c(c1c2[nH]cc1)ccc2Cl)=O Chemical compound CC(N(CC1)Cc2c1[n](C)nc2-c(c1c2[nH]cc1)ccc2Cl)=O IXQWNXJLNOFSRE-UHFFFAOYSA-N 0.000 description 1
- HWPHUYSBHLYXFP-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C)nc2-c1c(cc[nH]2)c2cc(C(OC)=O)c1)=O Chemical compound CC(N(CC1)Cc2c1[n](C)nc2-c1c(cc[nH]2)c2cc(C(OC)=O)c1)=O HWPHUYSBHLYXFP-UHFFFAOYSA-N 0.000 description 1
- RMTJHTPDLSMGNR-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C)nc2-c1c(cc[nH]2)c2cc(OC)c1)=O Chemical compound CC(N(CC1)Cc2c1[n](C)nc2-c1c(cc[nH]2)c2cc(OC)c1)=O RMTJHTPDLSMGNR-UHFFFAOYSA-N 0.000 description 1
- YAOPYMWNGQHROH-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C)nc2-c1c(cc[nH]2)c2ccc1)=O Chemical compound CC(N(CC1)Cc2c1[n](C)nc2-c1c(cc[nH]2)c2ccc1)=O YAOPYMWNGQHROH-UHFFFAOYSA-N 0.000 description 1
- XGLAIMCDIMBGPK-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C1CCOCC1)nc2-c(c1c2ccnc1)ccc2OC)=O Chemical compound CC(N(CC1)Cc2c1[n](C1CCOCC1)nc2-c(c1c2ccnc1)ccc2OC)=O XGLAIMCDIMBGPK-UHFFFAOYSA-N 0.000 description 1
- QRHSMFNSBKWHNZ-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C1CCOCC1)nc2-c(c1cnc2)cccc1c2Cl)=O Chemical compound CC(N(CC1)Cc2c1[n](C1CCOCC1)nc2-c(c1cnc2)cccc1c2Cl)=O QRHSMFNSBKWHNZ-UHFFFAOYSA-N 0.000 description 1
- GAVVBDXGDAIREU-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C1CCOCC1)nc2-c(c1cnc2)cccc1c2OC)=O Chemical compound CC(N(CC1)Cc2c1[n](C1CCOCC1)nc2-c(c1cnc2)cccc1c2OC)=O GAVVBDXGDAIREU-UHFFFAOYSA-N 0.000 description 1
- DXDMNVZXOSKMBM-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C1CCOCC1)nc2-c1c(C)[nH]c2c1cccc2)=O Chemical compound CC(N(CC1)Cc2c1[n](C1CCOCC1)nc2-c1c(C)[nH]c2c1cccc2)=O DXDMNVZXOSKMBM-UHFFFAOYSA-N 0.000 description 1
- VTCVXJOJHKXFNH-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C1CCOCC1)nc2-c1c(cnc(-c2c[n](C)nc2)c2)c2cc(C)c1)=O Chemical compound CC(N(CC1)Cc2c1[n](C1CCOCC1)nc2-c1c(cnc(-c2c[n](C)nc2)c2)c2cc(C)c1)=O VTCVXJOJHKXFNH-UHFFFAOYSA-N 0.000 description 1
- VCCZELIPLFSVQC-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C1CCOCC1)nc2-c1c(cnc(-c2c[n](C)nc2)c2)c2ccc1C)=O Chemical compound CC(N(CC1)Cc2c1[n](C1CCOCC1)nc2-c1c(cnc(-c2c[n](C)nc2)c2)c2ccc1C)=O VCCZELIPLFSVQC-UHFFFAOYSA-N 0.000 description 1
- DJSHZSFSVVWRLV-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C1CCOCC1)nc2-c1c(cnc(N(CC2)CC2C#N)c2)c2ccc1)=O Chemical compound CC(N(CC1)Cc2c1[n](C1CCOCC1)nc2-c1c(cnc(N(CC2)CC2C#N)c2)c2ccc1)=O DJSHZSFSVVWRLV-UHFFFAOYSA-N 0.000 description 1
- MURDGIZINCTSAI-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C1CCOCC1)nc2-c1c(cnc(N2CCCCC2)c2)c2ccc1)=O Chemical compound CC(N(CC1)Cc2c1[n](C1CCOCC1)nc2-c1c(cnc(N2CCCCC2)c2)c2ccc1)=O MURDGIZINCTSAI-UHFFFAOYSA-N 0.000 description 1
- FXGWPWRNOMGUEL-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C1CCOCC1)nc2-c1c(cnc(N2CCN(C)CC2)c2)c2ccc1)=O Chemical compound CC(N(CC1)Cc2c1[n](C1CCOCC1)nc2-c1c(cnc(N2CCN(C)CC2)c2)c2ccc1)=O FXGWPWRNOMGUEL-UHFFFAOYSA-N 0.000 description 1
- UHNWSNQEYDVJCQ-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C1CCOCC1)nc2-c1c(cncc2)c2c(CO)cc1)=O Chemical compound CC(N(CC1)Cc2c1[n](C1CCOCC1)nc2-c1c(cncc2)c2c(CO)cc1)=O UHNWSNQEYDVJCQ-UHFFFAOYSA-N 0.000 description 1
- IZPACEJNRRRHNL-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C1CCOCC1)nc2-c1c(cncc2C=C)c2ccc1)=O Chemical compound CC(N(CC1)Cc2c1[n](C1CCOCC1)nc2-c1c(cncc2C=C)c2ccc1)=O IZPACEJNRRRHNL-UHFFFAOYSA-N 0.000 description 1
- VEGQMQNNMPHWTC-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C1CCOCC1)nc2-c1c[nH]c2c1cccc2)=O Chemical compound CC(N(CC1)Cc2c1[n](C1CCOCC1)nc2-c1c[nH]c2c1cccc2)=O VEGQMQNNMPHWTC-UHFFFAOYSA-N 0.000 description 1
- IUALVYSGFLFDGK-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C1CCOCC1)nc2-c1c[n](C)c2c1cccc2)=O Chemical compound CC(N(CC1)Cc2c1[n](C1CCOCC1)nc2-c1c[n](C)c2c1cccc2)=O IUALVYSGFLFDGK-UHFFFAOYSA-N 0.000 description 1
- JEJLXAUUWSWJGH-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C1CCOCC1)nc2-c1cc(Cl)cc2c1cnc(-c1c[n](C)nc1)c2)=O Chemical compound CC(N(CC1)Cc2c1[n](C1CCOCC1)nc2-c1cc(Cl)cc2c1cnc(-c1c[n](C)nc1)c2)=O JEJLXAUUWSWJGH-UHFFFAOYSA-N 0.000 description 1
- YMJZTJARHXMQNO-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C1CCOCC1)nc2-c1ccc(C)c2c1cncc2)=O Chemical compound CC(N(CC1)Cc2c1[n](C1CCOCC1)nc2-c1ccc(C)c2c1cncc2)=O YMJZTJARHXMQNO-UHFFFAOYSA-N 0.000 description 1
- XJAYQWZRDYTMBJ-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C1CCOCC1)nc2-c1cccc2c(C)c(-c3c[n](C)nc3)ncc12)=O Chemical compound CC(N(CC1)Cc2c1[n](C1CCOCC1)nc2-c1cccc2c(C)c(-c3c[n](C)nc3)ncc12)=O XJAYQWZRDYTMBJ-UHFFFAOYSA-N 0.000 description 1
- HPNNACJOXIUFQN-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C1CCOCC1)nc2-c1cccc2c(CO)cncc12)=O Chemical compound CC(N(CC1)Cc2c1[n](C1CCOCC1)nc2-c1cccc2c(CO)cncc12)=O HPNNACJOXIUFQN-UHFFFAOYSA-N 0.000 description 1
- YKJCGHAYZPQUNB-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C1CCOCC1)nc2-c1cccc2c1[nH]cc2)=O Chemical compound CC(N(CC1)Cc2c1[n](C1CCOCC1)nc2-c1cccc2c1[nH]cc2)=O YKJCGHAYZPQUNB-UHFFFAOYSA-N 0.000 description 1
- DBRHAVKKINQCFP-DLKOBCSISA-N CC(N(CC1)Cc2c1[n](C1COC1)nc2-c1c[nH]c2c1ccc(/C(/C=N)=C/NC)c2)=O Chemical compound CC(N(CC1)Cc2c1[n](C1COC1)nc2-c1c[nH]c2c1ccc(/C(/C=N)=C/NC)c2)=O DBRHAVKKINQCFP-DLKOBCSISA-N 0.000 description 1
- VJMYKALJTHINKT-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](C1COCC1)nc2-c1c[nH]c2c1ccc(-c1c[n](C)nc1)c2)=O Chemical compound CC(N(CC1)Cc2c1[n](C1COCC1)nc2-c1c[nH]c2c1ccc(-c1c[n](C)nc1)c2)=O VJMYKALJTHINKT-UHFFFAOYSA-N 0.000 description 1
- MPXKOIKIRQBXKT-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](CC1CC1)nc2-c1c(cc[nH]2)c2ccc1)=O Chemical compound CC(N(CC1)Cc2c1[n](CC1CC1)nc2-c1c(cc[nH]2)c2ccc1)=O MPXKOIKIRQBXKT-UHFFFAOYSA-N 0.000 description 1
- RWGXTFKQGCEQMJ-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](CC1CC1)nc2-c1c[nH]c2c1cccc2)=O Chemical compound CC(N(CC1)Cc2c1[n](CC1CC1)nc2-c1c[nH]c2c1cccc2)=O RWGXTFKQGCEQMJ-UHFFFAOYSA-N 0.000 description 1
- YSSFCOVCRFYODP-UHFFFAOYSA-N CC(N(CC1)Cc2c1[n](CC1CC1)nc2-c1ccc(C)c2c1cc[nH]2)=O Chemical compound CC(N(CC1)Cc2c1[n](CC1CC1)nc2-c1ccc(C)c2c1cc[nH]2)=O YSSFCOVCRFYODP-UHFFFAOYSA-N 0.000 description 1
- UEFJFQPLVYIOOV-SFHVURJKSA-N CC(N(CC1)Cc2c1[n]([C@@H]1COCC1)nc2-c1cccc2c1ccc(-c1c[n](C)nc1)n2)=O Chemical compound CC(N(CC1)Cc2c1[n]([C@@H]1COCC1)nc2-c1cccc2c1ccc(-c1c[n](C)nc1)n2)=O UEFJFQPLVYIOOV-SFHVURJKSA-N 0.000 description 1
- GHQQSOMXAFNIIX-UHFFFAOYSA-O CCc1c(cccc2C(C(CN(CC3)C(C)=O)=C3NC3CCOCC3)=[NH2+])c2cnc1 Chemical compound CCc1c(cccc2C(C(CN(CC3)C(C)=O)=C3NC3CCOCC3)=[NH2+])c2cnc1 GHQQSOMXAFNIIX-UHFFFAOYSA-O 0.000 description 1
- LDVUEFAKDIGXQX-UHFFFAOYSA-N CCc1ccc(-c2n[n](C3CCOCC3)c(CC3)c2CN3C(C)=O)c2c1ccnc2 Chemical compound CCc1ccc(-c2n[n](C3CCOCC3)c(CC3)c2CN3C(C)=O)c2c1ccnc2 LDVUEFAKDIGXQX-UHFFFAOYSA-N 0.000 description 1
- FAQWKGYIDUQQEE-UHFFFAOYSA-N CNC(N(CC1)Cc2c1[n](C1CCOCC1)c(C#N)c2C(CC=Cc1c2)c1cnc2-c1c[n](CCNC(N(CC2)Cc3c2[n](C2CCOCC2)nc3-c2c(CCCN(C3)c4c[n](C)nc4)c3ccc2)=O)nc1)=O Chemical compound CNC(N(CC1)Cc2c1[n](C1CCOCC1)c(C#N)c2C(CC=Cc1c2)c1cnc2-c1c[n](CCNC(N(CC2)Cc3c2[n](C2CCOCC2)nc3-c2c(CCCN(C3)c4c[n](C)nc4)c3ccc2)=O)nc1)=O FAQWKGYIDUQQEE-UHFFFAOYSA-N 0.000 description 1
- DRWVHZPKNZHPFP-UHFFFAOYSA-N COc(cc1)ccc1N(Cc1c2c(I)ccc1)C2=O Chemical compound COc(cc1)ccc1N(Cc1c2c(I)ccc1)C2=O DRWVHZPKNZHPFP-UHFFFAOYSA-N 0.000 description 1
- NZOVMAWNOOEQJP-UHFFFAOYSA-N C[n]1ncc(N(CCc(c2ccc3)c3[IH]C)C2=O)c1 Chemical compound C[n]1ncc(N(CCc(c2ccc3)c3[IH]C)C2=O)c1 NZOVMAWNOOEQJP-UHFFFAOYSA-N 0.000 description 1
- RZLGPVWNRCQORH-UHFFFAOYSA-N C[n]1ncc(N(Cc2ccccc2C2)C2=O)c1 Chemical compound C[n]1ncc(N(Cc2ccccc2C2)C2=O)c1 RZLGPVWNRCQORH-UHFFFAOYSA-N 0.000 description 1
- IPWVATCRLKASLP-UHFFFAOYSA-N Cc(c1ccc2)c(-c3c[n](C)nc3)ncc1c2-c1n[n](C2CCOCC2)c(CC2)c1CN2C(NC)=O Chemical compound Cc(c1ccc2)c(-c3c[n](C)nc3)ncc1c2-c1n[n](C2CCOCC2)c(CC2)c1CN2C(NC)=O IPWVATCRLKASLP-UHFFFAOYSA-N 0.000 description 1
- MQPVQCUKTCDLKI-UHFFFAOYSA-N Cc1c(CC(N(C)C2)=O)c2ccc1 Chemical compound Cc1c(CC(N(C)C2)=O)c2ccc1 MQPVQCUKTCDLKI-UHFFFAOYSA-N 0.000 description 1
- TZPZTDFDCDHPHG-UHFFFAOYSA-N Cc1cccc2c1cnc(-c(cc1)cnc1C(NC)=O)c2F Chemical compound Cc1cccc2c1cnc(-c(cc1)cnc1C(NC)=O)c2F TZPZTDFDCDHPHG-UHFFFAOYSA-N 0.000 description 1
- PSBDRZJULJXNAT-UHFFFAOYSA-N N#Cc1cc(NC(c2cccc(I)c2)=O)ccc1 Chemical compound N#Cc1cc(NC(c2cccc(I)c2)=O)ccc1 PSBDRZJULJXNAT-UHFFFAOYSA-N 0.000 description 1
- QRKLKNHKYLIORU-UHFFFAOYSA-N O=C(Cc1c(C2)cccc1I)N2C1CCCC1 Chemical compound O=C(Cc1c(C2)cccc1I)N2C1CCCC1 QRKLKNHKYLIORU-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2016083118 | 2016-05-24 | ||
| CNPCT/CN2016/083118 | 2016-05-24 | ||
| PCT/US2017/034326 WO2017205538A1 (en) | 2016-05-24 | 2017-05-24 | Pyrazolopyridine derivatives for the treatment of cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019516759A JP2019516759A (ja) | 2019-06-20 |
| JP2019516759A5 true JP2019516759A5 (https=) | 2020-07-02 |
| JP7014736B2 JP7014736B2 (ja) | 2022-02-01 |
Family
ID=59055277
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018561557A Expired - Fee Related JP7014736B2 (ja) | 2016-05-24 | 2017-05-24 | がんの処置のためのピラゾロピリジン誘導体 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US11247989B2 (https=) |
| EP (1) | EP3464286B1 (https=) |
| JP (1) | JP7014736B2 (https=) |
| CN (1) | CN109476663B (https=) |
| MA (1) | MA45146A (https=) |
| WO (1) | WO2017205538A1 (https=) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2928773T3 (es) | 2017-01-17 | 2022-11-22 | Heparegenix Gmbh | Inhibidores de proteína cinasas para fomentar la regeneración hepática o reducir o prevenir la muerte de hepatocitos |
| RU2020131507A (ru) * | 2018-03-29 | 2022-05-04 | Боард Оф Реджентс, Де Юниверсити Оф Техас Систем | Имидазопиперазиновые ингибиторы белков-активаторов транскрипции |
| WO2019195846A1 (en) | 2018-04-06 | 2019-10-10 | Board Of Regents, The University Of Texas System | Imidazopiperazinone inhibitors of transcription activating proteins |
| CN110878042B (zh) * | 2018-09-05 | 2021-06-01 | 新发药业有限公司 | 一种n-取代基哌啶-3-酮的制备方法 |
| CN111320621B (zh) * | 2018-12-14 | 2022-10-04 | 中国科学院广州生物医药与健康研究院 | 一种吲嗪类化合物及其制备方法和应用 |
| WO2020173440A1 (en) * | 2019-02-27 | 2020-09-03 | Cullgen (Shanghai), Inc. | Cyclic-amp response element binding protein (cbp) and/or adenoviral e1a binding protein of 300 kda (p300) degradation compounds and methods of use |
| US20220135538A1 (en) * | 2019-02-27 | 2022-05-05 | Constellation Pharmaceuticals, Inc. | P300/cbp hat inhibitors and methods for their use |
| SG11202110714VA (en) * | 2019-04-09 | 2021-10-28 | Plexxikon Inc | Condensed azines for ep300 or cbp modulation and indications therefor |
| JP7539382B2 (ja) | 2019-07-29 | 2024-08-23 | 武田薬品工業株式会社 | 複素環化合物 |
| TW202120095A (zh) * | 2019-08-05 | 2021-06-01 | 美商美國禮來大藥廠 | 7,8-二氫-4H-吡唑并[4,3-c]氮呯-6-酮化合物 |
| EP4097105A1 (en) * | 2020-01-27 | 2022-12-07 | Bristol-Myers Squibb Company | 1h-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (tlr7) agonists |
| CN111440161B (zh) * | 2020-05-15 | 2023-04-14 | 中国药科大学 | 一种具有par4拮抗活性的二环杂芳基类化合物及其应用 |
| US12425396B2 (en) * | 2020-06-10 | 2025-09-23 | Beijing Xiaomi Mobile Software Co., Ltd. | Biometric feature verification method and apparatus, electronic device, and storage medium |
| US11691971B2 (en) | 2020-06-19 | 2023-07-04 | Incyte Corporation | Naphthyridinone compounds as JAK2 V617F inhibitors |
| WO2021257863A1 (en) | 2020-06-19 | 2021-12-23 | Incyte Corporation | Pyrrolotriazine compounds as jak2 v617f inhibitors |
| CR20230057A (es) | 2020-07-02 | 2023-08-15 | Incyte Corp | Compuestos tríciclicos de urea como inhibidores de jak2 v617f |
| US11767323B2 (en) | 2020-07-02 | 2023-09-26 | Incyte Corporation | Tricyclic pyridone compounds as JAK2 V617F inhibitors |
| US11661422B2 (en) | 2020-08-27 | 2023-05-30 | Incyte Corporation | Tricyclic urea compounds as JAK2 V617F inhibitors |
| CN112079826B (zh) * | 2020-09-17 | 2022-07-29 | 广州中医药大学(广州中医药研究院) | 一类甾体合成酶抑制剂及其治疗应用 |
| CA3193745A1 (en) | 2020-10-02 | 2022-04-07 | Kang Le | Imidazopiperazine inhibitors of transcription activating proteins |
| EP4221708A4 (en) | 2020-10-02 | 2024-11-06 | Board of Regents, The University of Texas System | IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION-ACTIVATING PROTEINS |
| US20230399303A1 (en) * | 2020-10-26 | 2023-12-14 | Yale University | Macrophage Migration Inhibitory Factor Inhibitors, and Methods of Making and Using Same |
| US11919908B2 (en) | 2020-12-21 | 2024-03-05 | Incyte Corporation | Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors |
| US20240122941A1 (en) * | 2020-12-25 | 2024-04-18 | National Cancer Center | Therapy based on synthetic lethality in swi/snf complex-dysfunction cancer |
| AR125273A1 (es) | 2021-02-25 | 2023-07-05 | Incyte Corp | Lactamas espirocíclicas como inhibidores de jak2 v617f |
| PT4426434T (pt) | 2021-11-02 | 2025-11-24 | Flare Therapeutics Inc | Agonistas inversos de pparg e suas utilizações |
| IL312642A (en) | 2021-11-12 | 2024-07-01 | Insilico Medicine Ip Ltd | Small molecule inhibitors of ubiquitin specific protease 1 (usp1) and uses thereof |
| AU2023235313A1 (en) | 2022-03-17 | 2024-10-03 | Incyte Corporation | Tricyclic urea compounds as jak2 v617f inhibitors |
| WO2024019698A1 (en) | 2022-07-18 | 2024-01-25 | Jsr Corporation | Photocatalytic synthesis of alpha, beta unsaturated carbonyl compounds and their intermediates |
| CN117843618A (zh) * | 2022-08-29 | 2024-04-09 | 北京沐华生物科技有限责任公司 | 一种ep300/cbp调节剂及其制备方法和用途 |
| CN115710249B (zh) * | 2022-11-14 | 2024-11-19 | 广东工业大学 | 一种多取代异喹啉和1,6-萘啶化合物的制备方法及光电材料常见分子骨架 |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU22545A1 (es) | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
| DK27383A (da) * | 1982-02-17 | 1983-08-18 | Lepetit Spa | Fremgangsmaade til fremstilling af pyrazol(4,3-c)pyridiner |
| US4943533A (en) | 1984-03-01 | 1990-07-24 | The Regents Of The University Of California | Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor |
| EP0491007B1 (en) | 1989-09-08 | 1996-03-13 | The Johns Hopkins University | Structural alterations of the egf receptor gene in human gliomas |
| GB9300059D0 (en) | 1992-01-20 | 1993-03-03 | Zeneca Ltd | Quinazoline derivatives |
| GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
| DE69428764T2 (de) | 1993-12-24 | 2002-06-20 | Merck Patent Gmbh | Immunokonjugate |
| IL112249A (en) | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
| IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
| US5654307A (en) | 1994-01-25 | 1997-08-05 | Warner-Lambert Company | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family |
| WO1996003397A1 (en) | 1994-07-21 | 1996-02-08 | Akzo Nobel N.V. | Cyclic ketone peroxide formulations |
| US5804396A (en) | 1994-10-12 | 1998-09-08 | Sugen, Inc. | Assay for agents active in proliferative disorders |
| DE69536015D1 (de) | 1995-03-30 | 2009-12-10 | Pfizer Prod Inc | Chinazolinone Derivate |
| GB9508565D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| JPH11507535A (ja) | 1995-06-07 | 1999-07-06 | イムクローン システムズ インコーポレイテッド | 腫瘍の成長を抑制する抗体および抗体フラグメント類 |
| SI9620103A (sl) | 1995-07-06 | 1998-10-31 | Novartis Ag | Pirolopirimidini in postopki za njihovo pripravo |
| US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
| GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| EA001595B1 (ru) | 1996-04-12 | 2001-06-25 | Варнер-Ламберт Компани | Необратимые ингибиторы тирозинкиназ |
| AR007857A1 (es) | 1996-07-13 | 1999-11-24 | Glaxo Group Ltd | Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios uso en medicina ycomposiciones farmaceuticas que los contienen. |
| ID18494A (id) | 1996-10-02 | 1998-04-16 | Novartis Ag | Turunan pirazola leburan dan proses pembuatannya |
| UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
| US6002008A (en) | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| WO1998050038A1 (en) | 1997-05-06 | 1998-11-12 | American Cyanamid Company | Use of quinazoline compounds for the treatment of polycystic kidney disease |
| ZA986729B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitors of tyrosine kinases |
| ZA986732B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
| TW436485B (en) | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
| BR9814116A (pt) | 1997-11-06 | 2000-10-03 | American Cyanamid Co | Uso de derivados de quinazolina como inibidores de cinase de tirosina para tratamento de pólipo colÈnico |
| EA003786B1 (ru) | 1998-11-19 | 2003-10-30 | Варнер Ламберт Компани | N-[4-(3-хлор-4-фторфениламино)-7-(3-морфолин-4-илпропокси)хиназолин-6-ил]акриламид - необратимый ингибитор тирозинкиназ |
| CA2493637A1 (en) | 2002-07-25 | 2004-02-12 | Manuela Villa | Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| EP1526852A1 (en) | 2002-07-25 | 2005-05-04 | Pharmacia Italia S.p.A. | Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| US20070037790A1 (en) | 2003-03-11 | 2007-02-15 | Francesca Abrate | Bicyclo-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| DK2439273T3 (da) | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
| PT1907424E (pt) | 2005-07-01 | 2015-10-09 | Squibb & Sons Llc | Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1) |
| EP1968976A1 (en) | 2005-12-12 | 2008-09-17 | NERVIANO MEDICAL SCIENCES S.r.l. | Substituted pyrazolo [4,3-c] pyridine derivatives active as kinase inhibitors |
| WO2007099166A1 (en) | 2006-03-03 | 2007-09-07 | Nerviano Medical Sciences S.R.L. | Pyrazolo-pyridine derivatives active as kinase inhibitors |
| KR101600634B1 (ko) | 2007-12-28 | 2016-03-07 | 미쓰비시 타나베 파마 코퍼레이션 | 항암제 |
| CN101970499B (zh) | 2008-02-11 | 2014-12-31 | 治疗科技公司 | 用于肿瘤治疗的单克隆抗体 |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| CL2009001158A1 (es) | 2008-05-15 | 2009-10-23 | Nerviano Medical Sciences Srl | Compuestos derivados de los acidos carboxilicos, tales como 5,6-dihiro-4h-pirrolo[3,4-c]pirazol, furo[3,2-c]pirazol, tieno[2,3-c]pirazol, 4,5,6,7-tetrahidropirazol[4,3-c]piridina e indazol; composicion farmaceutica; y su uso en el tratamiento de trastornos proliferativos celulares asociados a la actividad de proteina quinasa alterada, tal como el cancer. |
| WO2009158394A1 (en) * | 2008-06-25 | 2009-12-30 | Bristol-Myers Squibb Company | Diketo azolopiperidines and azolopiperazines as anti-hiv agents |
| JP2012500855A (ja) | 2008-08-25 | 2012-01-12 | アンプリミューン、インコーポレーテッド | Ｐｄ−１アンタゴニストおよび感染性疾患を処置するための方法 |
| EP3255060A1 (en) | 2008-12-09 | 2017-12-13 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| WO2011066342A2 (en) | 2009-11-24 | 2011-06-03 | Amplimmune, Inc. | Simultaneous inhibition of pd-l1/pd-l2 |
| CN101812063B (zh) | 2010-03-18 | 2012-04-25 | 中国医学科学院医药生物技术研究所 | α-萘磺酰胺基五元杂环类化合物及其抑瘤活性 |
| WO2013037389A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | Indanyl-substituted 4,5,6,7-tetrahydro-1h-pyrazolo[4,3-c]pyridines, their use as medicament, and pharmaceutical preparations comprising them |
| WO2013097052A1 (en) | 2011-12-30 | 2013-07-04 | Abbott Laboratories | Bromodomain inhibitors |
| WO2013148114A1 (en) | 2012-03-30 | 2013-10-03 | University Of Florida Research Foundation, Inc. | P300/cbp inhibitors and methods of use |
| WO2014138727A1 (en) | 2013-03-08 | 2014-09-12 | Board Of Regents, The University Of Texas System | Suppression of malignant mesothelioma by overexpression or stimulation of endothelial protein c receptors (epcr) |
| EP2993174A1 (en) * | 2014-09-08 | 2016-03-09 | Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH | Pyrazolopyridine derivatives and their use in therapy |
| EP3632915A1 (en) | 2014-11-27 | 2020-04-08 | Genentech, Inc. | 4,5,6,7-tetrahydro-1 h-pyrazolo[4,3-c]pyridin-3-amine compounds as cbp and/or ep300 inhibitors |
-
2017
- 2017-05-24 JP JP2018561557A patent/JP7014736B2/ja not_active Expired - Fee Related
- 2017-05-24 MA MA045146A patent/MA45146A/fr unknown
- 2017-05-24 WO PCT/US2017/034326 patent/WO2017205538A1/en not_active Ceased
- 2017-05-24 CN CN201780045658.6A patent/CN109476663B/zh active Active
- 2017-05-24 EP EP17729963.3A patent/EP3464286B1/en active Active
-
2018
- 2018-11-21 US US16/198,581 patent/US11247989B2/en not_active Expired - Fee Related
-
2022
- 2022-01-06 US US17/570,139 patent/US20220127265A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019516759A5 (https=) | ||
| JP2019516757A5 (https=) | ||
| JP2017530176A5 (https=) | ||
| JP2017533250A5 (https=) | ||
| JP2018510851A5 (https=) | ||
| JP2017537100A5 (https=) | ||
| JP2017526696A5 (https=) | ||
| JP2017533249A5 (https=) | ||
| JP6066421B2 (ja) | 癌の治療のための低酸素活性化プロドラッグおよび血管新生阻害剤の投与方法 | |
| JP2017533248A5 (https=) | ||
| US10993945B2 (en) | CDK8-CDK19 selective inhibitors and their use in anti-metastatic and chemopreventative methods for cancer | |
| JP6835472B2 (ja) | 癌の処置のための組成物 | |
| JP2017525740A5 (https=) | ||
| JP2018501287A5 (https=) | ||
| JP2017530984A5 (https=) | ||
| CN103458896B (zh) | 用于治疗癌症的方法 | |
| JP2018505169A5 (https=) | ||
| RU2018138828A (ru) | Уменьшение массы опухоли путем введения ccr1 антагонистов в комбинации с pd-1 ингибиторами или pd-l1 ингибиторами | |
| JP2009541223A5 (https=) | ||
| JP2014510078A5 (https=) | ||
| JP2018507191A5 (https=) | ||
| JP2015514796A5 (https=) | ||
| CN104470509A (zh) | 剂量范围在2至30mg/kg的地塞米诺或其衍生物在癌症治疗中的用途 | |
| CN104755455A (zh) | 可用于治疗癌症的巨大戟醇衍生化合物 | |
| RU2011139157A (ru) | Производное трициклического пиразолопиримидина |